Cencora (COR) Surges 2.8% on Strong Earnings and Strategic Acquisitions: Is This the Start of a Bullish Run?

Summary
• Cencora (COR) trades at $360.29, up 2.81% intraday with a 52-week high of $377.54.
• Q1 revenue hits $85.9B, EPS beats estimates by $0.04, and guidance raised to $17.45–$17.60.
• OneOncology acquisition strengthens specialty healthcare footprint, driving investor optimism.
• Sector leader Cardinal Health (CAH) rises 2.23%, signaling broader healthcare distribution sector strength.
Cencora’s stock surged 2.8% on robust Q1 earnings, strategic acquisitions, and raised guidance. The company’s $85.9B revenue and $4.08 EPS outperformed expectations, while its acquisition of OneOncology solidified its position in oncology services. With the healthcare distribution sector showing resilience, investors are weighing the stock’s momentum against technical indicators and options activity.

Earnings Beat and Strategic Expansion Fuel Rally
Cencora’s 2.8% intraday gain stems from a combination of strong Q1 earnings and strategic acquisitions. The company reported $85.9B in revenue, a 5.5% year-over-year increase, with adjusted EPS of $4.08, surpassing the $4.04 consensus. Management raised full-year guidance to $17.45–$17.60 EPS, citing the acquisition of OneOncology, which expanded its oncology-focused management services. This move not only diversified Cencora’s revenue streams but also positioned it as a key player in the high-growth specialty healthcare segment. Analysts highlighted the acquisition’s potential to drive long-term margin expansion, particularly in the U.S. Healthcare Solutions segment, which saw a 21% surge in operating income.

Healthcare Distributors Rally as Cencora Outpaces Peers
The healthcare distribution sector, led by Cardinal Health (CAH) with a 2.23% intraday gain, is showing resilience amid rising demand for specialty pharmaceuticals. Cencora’s 2.8% rally outperformed CAH, reflecting its strategic focus on oncology and specialty services. While CAH’s recent earnings highlighted cost pressures in its generic drug segment, Cencora’s acquisition of OneOncology and Retina Consultants of America provided a clearer growth trajectory. The sector’s 0.68% beta suggests lower volatility compared to the S&P 500, but Cencora’s aggressive expansion and higher leverage ratio (3.62) position it as a more speculative play within the group.

Options and ETFs to Capitalize on Cencora’s Momentum
• 200-day MA: $316.63 (well below current price); RSI: 48.92 (neutral); MACD: 2.99 (bullish divergence).
• Bollinger Bands: Price at $360.29, above the upper band of $370.02, indicating overbought conditions.
• Key support/resistance: 30D support at $345.69, 200D support at $291.87; 30D resistance at $346.41.
• Leverage ETFs: None available; focus on options for directional bets.

Top Options Picks:
1. COR20260220C360 (Call, $360 strike, 2026-02-20):
• IV: 29.30% (moderate)
• Delta: 0.528 (moderate sensitivity)
• Theta: -1.177 (high time decay)
• Gamma: 0.0254 (high sensitivity to price swings)
• Turnover: 7,419 (liquid)
• Leverage: 54.45% (high)
• Payoff at 5% upside ($378.30): $18.30 per contract.
This call option offers a balance of leverage and liquidity, ideal for capitalizing on short-term volatility. The high gamma ensures responsiveness to price swings, while the moderate IV suggests reasonable premium costs.
2. COR20260220C380 (Call, $380 strike, 2026-02-20):
• IV: 25.50% (reasonable)
• Delta: 0.087 (low sensitivity)
• Theta: -0.268 (low time decay)
• Gamma: 0.0117 (moderate sensitivity)
• Turnover: 6,133 (liquid)
• Leverage: 667.57% (extreme)
• Payoff at 5% upside ($378.30): $0 (out-of-the-money).
While the extreme leverage is enticing, this option is speculative and only viable if the stock breaks above $380. The low delta and theta make it a high-risk, high-reward play.
Action: Aggressive bulls should prioritize COR20260220C360 for a near-term breakout above $364.67 (intraday high). Conservative traders may use the $360 strike as a hedge against a pullback to the 30D support at $345.69.

Backtest Cencora Stock Performance
The backtest of COR's performance following a 3% intraday surge from 2022 to the present shows favorable results. The 3-day win rate is 55.27%, the 10-day win rate is 59.95%, and the 30-day win rate is 68.62%, indicating that COR tends to experience positive returns in the short term after the intraday surge. The maximum return during the backtest period was 5.86%, which occurred on day 59, suggesting that there is potential for significant gains following the 3% increase.

Cencora’s Rally Gains Momentum: What’s Next for the Healthcare Giant?
Cencora’s 2.8% surge reflects strong earnings, strategic acquisitions, and a resilient healthcare distribution sector. With Cardinal Health (CAH) rising 2.23%, the sector remains a key driver of momentum. Technical indicators suggest overbought conditions, but the stock’s 52-week high and elevated RSI indicate sustained demand. Investors should monitor the $360.29 level for a potential pullback and the $370.02 Bollinger Band upper limit for continuation. For options traders, the COR20260220C360 call offers a high-leverage, liquid bet on a breakout. Act now: Buy the $360 call if the stock holds above $351.00 (intraday low); exit if it fails to clear $364.67.